# Inside the KLOW Stack: The Four Peptides — KLOW Peptide Component Deep Dive > The klow stack broken down: KPV, GHK-Cu, BPC-157 and TB-500 — each component's structure, mechanism, and research literature. KLOW peptide component deep dive. Each component's structure, mechanism, and research literature read separately. The composition rationale and the gaps noted plainly. ## In plain English The klow stack is four separate research peptides in one vial. That sentence is the most important thing to understand about KLOW peptide: it is not one compound. It is four chemically distinct peptides — KPV, GHK-Cu, BPC-157, and TB-500 — dissolved together at fixed amounts. The four are not random. The composition logic is that they occupy four different nodes in the biology of tissue repair: KPV dials down inflammation; GHK-Cu rebuilds the matrix around the repair site; BPC-157 drives the new blood-vessel supply that healing tissue needs; and TB-500 helps cells migrate across the wound site. These four steps are complementary — not redundant, not redundant with each other. Here is what the research does and does not say: each of these four peptides has a body of individual studies behind it. The combination has zero controlled studies. Everything said about what KLOW does as a blend is extrapolation from the individual research. This page lays out each component in plain language, with its evidence and its honest limits. ## KLOW KLOW is a co-formulated research blend — four peptides co-lyophilized at fixed ratios in one vial. The most widely cited composition is 80 mg total: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg. 'KLOW' is not a registered pharmaceutical name; no FDA-approved KLOW product exists. The blend is a research-only co-formulation. The four components do not fuse into a new molecule. They remain four distinct chemical species in solution, each with its own pharmacokinetic profile, its own target tissue, and its own half-life. The vial co-delivers them — it does not merge them. ## KPV — the anti-inflammatory arm **Structure:** L-Lys-L-Pro-L-Val (CAS 67727-97-3, MW 342.44 Da). The C-terminal tripeptide of alpha-melanocyte-stimulating hormone (residues 11–13). Sequence: Lysine-Proline-Valine. **Mechanism:** KPV is actively transported into intestinal epithelial cells and macrophages via PepT1 (SLC15A1), the di/tripeptide transporter upregulated in inflamed gut tissue. At nanomolar concentrations it inhibits NF-kappaB nuclear import and MAPK (ERK/p38) signaling and reduces secretion of TNF-alpha, IL-6, IL-1beta, and IL-8 [3]. Its anti-inflammatory action in peritonitis was characterized as mechanistically distinct from core alpha-MSH peptides — likely directed at IL-1beta function, independent of melanocortin receptors [9]. **Research evidence:** Oral KPV reduced the severity of DSS- and TNBS-induced colitis in mice [3]. KPV-treated mice in an IBD adoptive-transfer model showed earlier recovery and reduced myeloperoxidase activity, with activity retained in MC1R-deficient animals [10]. PepT1-targeted KPV nanoparticle formulations in colitis models further improved outcomes relative to non-targeted delivery [8, 12]. **Limits:** No approved KPV monotherapy. No published human pharmacokinetic or efficacy trial. ## GHK-Cu — the matrix and transcriptome arm **Structure:** Gly-His-Lys chelated 1:1 to Cu(II) (CAS 89030-95-5, MW 402.92 Da). Naturally present in human plasma at approximately 200 ng/mL at age 20, declining to ~80 ng/mL by age 60 [4]. First isolated from human plasma by Loren Pickart in 1973. **Mechanism:** Stimulates synthesis of procollagen I and IV, dermatan sulfate, chondroitin sulfate, and the proteoglycan decorin in fibroblasts at nanomolar concentrations. Modulates approximately 31% of human protein-coding genes at a 50%-or-greater threshold, with strongest signals on extracellular-matrix remodeling, DNA repair, antioxidant defense, and the ubiquitin-proteasome system [5]. Reduces colitis severity through the SIRT1/STAT3 pathway and restores the epithelial barrier [13]. Supplies copper(II) for lysyl oxidase (the copper-dependent enzyme that crosslinks collagen and elastin). **Research evidence:** Topical GHK-Cu increased collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid in placebo-controlled topical data [4]. Decades of topical cosmetic and wound-healing human data; no approved systemic indication. **Limits:** GHK-Cu's human data are topical and cosmetic. No approved systemic product. At 50 mg/80 mg vial share, copper(II) load is the highest of any peptide stack in this class — a consideration for anyone with copper-handling disorders such as Wilson's disease. ## BPC-157 — the angiogenic and tissue-repair arm **Structure:** Synthetic 15-amino-acid peptide Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (CAS 137525-51-0, MW 1419.53 Da). Derived from a partial sequence of a protein identified in human gastric juice. **Mechanism:** Activates VEGFR2 phosphorylation with downstream PI3K/Akt/eNOS signaling — the primary angiogenic axis. Upregulates the growth-hormone receptor in tendon fibroblasts. Modulates the nitric-oxide system in a manner partly resistant to L-NAME inhibition, suggesting a distinct NO route [2]. **Research evidence:** BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, microscopic, and macroscopic measures at doses of 10 micrograms, 10 nanograms, and 10 picograms per rat intraperitoneally once daily [2]. A 2025 first-in-human IV pilot in two adults administered 10–20 mg intravenously with no adverse events [6]. A 2025 narrative review addressed BPC-157's safety framing [14]. **Limits:** Extensive rodent tissue-repair literature; very limited human data (n=2 in the safety pilot). FDA placed BPC-157 in category 2 of the 503A bulk-substances review. ## TB-500 — the cytoskeletal and wound-closure arm **Structure:** Synthetic N-acetylated heptapeptide Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (MW 889.02 Da). The LKKTET actin-binding motif of the 43-amino-acid native protein thymosin beta-4. TB-500 is the synthetic fragment; thymosin beta-4 (Tbeta4) is the full-length native protein. **Mechanism:** The LKKTET motif sequesters G-actin (monomeric globular actin), a step linked to cell migration and re-epithelialization. Full-length thymosin beta-4 additionally activates integrin-linked kinase and mobilizes epicardial progenitor cells — activities established for the native protein, not demonstrated for the TB-500 fragment. **Research evidence:** In a rat full-thickness wound model, native thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline; increased wound contraction by at least 11%; and raised collagen deposition and angiogenesis [1]. As little as 10 picograms stimulated keratinocyte migration 2–3-fold in vitro [1]. A 2024 review confirmed Tbeta4's effects are mediated through pro-resolving inflammation pathways [11]. A 2025 study showed Tbeta4-exosome hydrogels enhanced vascularized wound healing [15]. **Limits:** Most efficacy data are for full-length thymosin beta-4, not the TB-500 fragment. A 2026 sports medicine review noted scarce human safety data and regulatory concerns for TB-500 [7]. TB-500 is prohibited at all times under the WADA Prohibited List (S2) [7]. ## Why four peptides in one vial — the combination rationale The combination rationale is mechanistic: four arms addressing four complementary steps in the same repair cascade. KPV reduces the inflammatory signal that would otherwise slow repair. GHK-Cu rebuilds the matrix that repaired tissue needs to hold its structure. BPC-157 builds the new blood vessels that bring nutrients to the repair site. TB-500 moves cells across the injury to close the wound. Whether these four arms produce a meaningful synergy when co-dosed in a single vial is the unanswered question. No controlled study has tested KLOW against any subset. A pharmacokinetic mismatch is inherent — the four components have different half-lives and cannot all be at matched exposures simultaneously. The combination rationale is coherent; the combination evidence is absent. This is what this site — and the [KLOW research](/research) readout — makes explicit. --- A plain-spoken laboratory readout of the four-peptide component literature — each finding attributed to its source, the missing blend assay marked plainly in the margin.